Prev. Close*	36.56
Open*	36.3
Day's Range*	36.3 - 36.3
1-Year Change*	2.34%
Volume	N/A
Average Vol. (3m)	23.1621
52 wk Range	N/A
Market Cap	5196.89
P/E Ratio	N/A
Shares Outstanding	141.8M
Revenue	840.768
EPS	-0.02761
Dividend (Yield %)	N/A
Beta	0.76291
Next Earnings Date	Aug 2, 2022
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Ionis Pharmaceuticals Company profile

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; and Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

Industry:

Biotechnology & Medical Research (NEC)

2855 Gazelle Ct
CARLSBAD
CALIFORNIA 92010
US